MA
EVFM

MYDA Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

MYDA Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8,073
Closed -$420K – 247
2020
Q3 		$420K Sell
8,073
-11,927
-60% -$518K 0.22% 82
2020
Q2 		$1.23M Buy
+20,000
New +$1.35M 0.74% 46

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

MYDA Advisors's EVFM Position: Q4 2020 in Review

MYDA Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 8,073 shares — an estimated $420K sold.

MYDA Advisors first reported a position in EVFM in Q2 2020 and held it in 2 quarters. The position peaked at $1.23M in Q2 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • MYDA Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • MYDA Advisors sold 8,073 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $420K.
  • MYDA Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • MYDA Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $1.23M in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on MYDA Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.